Premature reduction of T-cell receptor rearrangement excision circle (TREC) levels in aSpA.
| Age | HC | aSpA | RA | HC vs aSpA | HC vs RA | aSpA vs RA |
|---|---|---|---|---|---|---|
| PBMCs | ||||||
| ≤35 | 1297 (30–9944) | 302 (34–1703) | 256.5 (0–3983) | 0.032 | 0.063 | 0.963 |
| 35.1–45 | 1326 (17–22 308) | 159 (10–2058) | 135 (0–22 857) | 0.033 | 0.087 | 0.923 |
| 45.1–55 | 83.5 (0–1942) | 51.5 (0–499) | 76 (5–268) | 0.860 | 1.000 | 0.713 |
| 55.1–65 | 72 (29–624) | 37 (4–87) | 28 (0–1596) | 0.223 | 0.391 | 0.583 |
| >65 | 19.5 (16–31) | 35 (11–815) | 33 (0–2633) | 0.480 | 0.686 | 0.711 |
| CD4+CD45RA+ | ||||||
| ≤35 | 2226 (77–64 444) | 525 (100–5264) | 984.5 (0–13 889) | 0.068 | 0.321 | 0.409 |
| 35.1–45 | 2505 (5–35 818) | 511.5 (33–5087) | 327 (0–162 800) | 0.136 | 0.039 | 0.244 |
| 45.1–55 | 148 (0–2347) | 217 (26–1815) | 153 (14–671) | 0.396 | 0.926 | 0.540 |
| 55.1–65 | 151 (52–359) | 138 (18–465) | 153 (10–4704) | 0.808 | 1.000 | 0.784 |
| >65 | 48 (11–68) | 49 (28–1858) | 96 (16–3076) | 0.724 | 0.179 | 0.958 |
| CD8+CD45RA+ | ||||||
| ≤35 | 2500 (146–55 368) | 467 (136–4720) | 716.5 (0–10 450) | 0.025 | 0.121 | 0.909 |
| 35.1–45 | 2123 (22–103 091) | 482.5 (15–4688) | 191 (0–71 800) | 0.181 | 0.073 | 0.560 |
| 45.1–55 | 137 (0–3517) | 154.5 (32–2413) | 185 (3–716) | 0.861 | 0.853 | 0.713 |
| 55.1–65 | 113 (40–415) | 122 (11–908) | 137.5 (0–12 625) | 0.935 | 1.000 | 0.715 |
| >65 | 63.5 (0–88) | 76 (18–2274) | 76 (6–5167) | 0.724 | 0.370 | 0.832 |
Overview of median (range) TREC levels (in copies/ng DNA) in PBMCs and T-cell subsets of HCs, patients with aSpA and patients with RA subdivided into groups according to their age. aSpA, axial spondyloarthritis; HC, healthy control; RA, rheumatoid arthritis.